AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

whitePaper | November 8, 2022

The Asia-Pacific region has emerged as a clinical trial hub due to the ease of regulatory compliance, low trial costs, rising patient population, and the availability of top clinical institutions.

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

whitePaper | October 25, 2022

To confirm the suitability of empty hard capsules for use in the application of quality-by-design (QbD) in the development and manufacturing of finished pharmaceutical products, the quality target product profile (QTPP) defined by eight critical quality attributes (CQA’s) was examined.